Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy

被引：0
|
作者：
Abed, A. [1 ]
Calapre, L. [2 ]
Bowyer, S. [3 ]
Millward, M. [4 ]
Gray, E. [2 ]
机构：
[1] Linear Clin Res, Oncol, Nedlands, WA, Australia
[2] Edith Cowan Univ, Med Sci, Joondalup, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia
[4] Linear Clin Res, Nedlands, WA, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
T-CR repertoire; Non-small cell lung cancer; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA12.04
引用
收藏
页码：S870 / S870
页数：1
相关论文
共 50 条
  • [31] Prognostic Value of HLA-I Homozygosity in Non-Small Cell Lung Cancer Patients Treated with Single Agent Immunotherapy
    Abed, A.
    Calapre, L.
    Lo, J.
    Correia, S.
    Bowyer, S.
    Chopra, A.
    Watson, M.
    Khattak, M.
    Millward, M.
    Gray, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S219 - S220
  • [32] Profiling of peripheral T cell receptor beta chain repertoire in non-small cell lung cancer (NSCLC) patients treated with anti-PD1
    Dong, N.
    Panizza, A.
    Moreno, A.
    Gallach, S.
    Zhang, F.
    Meri Abad, M.
    Aparisi Aparisi, F. D. A.
    Blasco Cordellat, A.
    Shaheen, I.
    Ferrero Gimeno, M.
    Calabuig-Farinas, S.
    Jantus Lewintre, E.
    Camps Herrero, C. J. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S724 - S724
  • [33] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [34] Impact of Pre-treatment Immunologic Parameters on the Outcomes of Early-Stage Non-Small Cell Lung Cancer (NSCLC)
    Adu-Quaye, M.
    Dube, S.
    Rathod, S.
    Dubey, A.
    Bashir, B. M.
    Lambert, P.
    Bucher, O.
    Kim, J.
    Leylek, A.
    Ahmed, N.
    Chowdhury, A. D.
    Koul, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E118 - E118
  • [35] Markers of efficacy in patients treated with immunotherapy for non-small cell lung cancer: a single cancer centre experience
    Sallam, Mostafa
    Haque, Farzana
    Mirza, Shagufta
    Brown, Victoria
    Lind, Michael
    Pillai, Annet
    LUNG CANCER, 2021, 156 : S38 - S39
  • [36] Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.
    Patil, Pradnya Dinkar
    Khunger, Monica
    Rakshit, Sagar
    Stevenson, James
    Pennell, Nathan A.
    Elson, Paul
    Velcheti, Vamsidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer
    Zhang, Yue-Hua
    Lu, Yuquan
    Lu, Hong
    Zhang, Meng-Wei
    Zhou, Yue-Min
    Li, Xiang-Lei
    Lv, Pin
    Zhao, Xiao-Yan
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (01) : 44 - 49
  • [38] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [39] Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy
    Bhagat, M.
    Warren, S.
    Elliott, N.
    Womack, C.
    Memeo, L.
    Colarossi, L.
    Cumberbatch, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
12345